Abstract
The symptoms of onychomycosis and their impact on personal appearance are important determinants of patients’ perceptions of their own health. The effect of onychomycosis is greater on psychosocial than physical functioning and is directly related to the extent of nail involvement.
This review identified a number of disease-targeted questionnaires that have been developed to assess the impact of onychomycosis and its treatment on health-related quality of life (HR-QOL). The instruments differ considerably in the extent to which they have been psychometrically tested. Most have been shown to provide both valid and reliable measurement of HR-QOL in patients with onychomycosis of the toes. However, not all have been tested in patients with fingernail disease. The generic and disease-targeted scales of most of the available questionnaires exhibit poor variability, which may limit their responsiveness to clinically important change.
Only one instrument, the Onychomycosis Disease-Specific Questionnaire, has been incorporated into a clinical trial. Thus, information relating to the impact of onychomycosis treatment on HR-QOL is limited. Future efforts should focus on the systematic evaluation of existing questionnaires in all populations for which they were developed. In addition, it is important that disease-targeted measures be included in future clinical trials so that a better understanding of the impact of onychomycosis treatment on patient HR-QOL may be gained.
Similar content being viewed by others
References
Midgley G, Moore MK, Cook JC, et al. Mycology of nail disorders. J Am Acad Dermatol 1994; 31 (3 Pt 2): S68–74
Arikian SR, Einarson TR, Kobelt-Nguyen G, et al. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. Br J Dermatol 1994; 130 Suppl. 43: 35–44
Einarson TR, Gupta AK, Shear NH, et al. Clinical and economic factors in the treatment of onychomycosis. Pharmacoeconomics 1996; 9 (4): 307–20
Marchetti A, Piech CT, McGhan WF, et al. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Clin Ther 1996; 18 (4): 757–77
Scher RK. Onychomycosis is more than a cosmetic problem. Br J Dermatol 1994; 130 Suppl. 43: 15
Lubeck DP, Patrick DL, McNulty P, et al. Quality of life persons with onychomycosis. Qual Life Res 1993; 341–8
Lubeck DP. Measuring health-related quality of life in onychomycosis. J Am Acad Dermatol 1998; 38 (5 Pt 3): S64–8
Drake LA, Patrick DL, Fleckman P, et al. The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol 1999; 41 (2 Pt 1): 189–96
Drake LA, Scher RK, Smith EB, et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol 1998; 38 (5 Pt 1): 702–4
Drake L. Quality of life issues for patients with fungal nail infections. AIDS Patient Care 1995; 9 Suppl 1: S15–7
Hong JJ, Stiller MJ, Menn E, et al. A pilot study to determine the biopsychosocial effects of onychomycosis on a northeastern American subpopulation [abstract]. J Invest Dermatol 1995; 104: 668
Whittam LR, Hay RJ. The impact of onychomycosis on quality of life. Clin Exp Dermatol 1997; 22 (2): 87–9
Elewski BE. The effect of toenail onychomycosis on patient quality of life. Int J Dermatol 1997; 36 (10): 754–6
Haneke E. Achilles Foot-Screening Project: background, objectives and design (discussion S17). J Eur Acad Dermatol Venereol 1999; 12 Suppl. 1: S2–5
Roseeuw D. Achilles Foot-Screening Project: preliminary results of patients screened by dermatologists (discussion S17). J Eur Acad Dermatol Venereol 1999; 12 Suppl. 1: S6–9
Opp K. Patients’ feelings and attitudes about their nail conditions. AIDS Patient Care 1995; 9 Suppl. 1: S18
Schein JR, Gause D, Stier DM, et al. Onychomycosis: baseline results of an observational study. J Am Podiatr Med Assoc 1997; 87 (11): 512–9
Lubeck DP, Gause D, Schein JR, et al. A health-related quality of life measure for use in patients with onychomycosis: a validation study. Qual Life Res 1999; 8 (1–2): 121–9
Lubeck DP, Schein JR, Gause D, et al. Health-related quality of life in patients with toenail onychomycosis: data from a 9-month observational study. JCOM 1999; 6 (8): 37–42
Turner RR, Testa MA. Measuring the impact of onychomycosis on patient quality of life. Qual Life Res 2000; 9 (1): 39–53
Pollak R, Billstein SA. Efficacy of terbinafine for toenail onychomycosis: a multicenter trial of various treatment durations. J Am Podiatr Med Assoc 2001; 91 (3): 127–31
Millikan LE, Powell DW, Drake LA. Quality of life for patients with onychomycosis. Int J Dermatol 1999; 38 Suppl. 2: 13–6
Mathes EW, Kahn A. Physical attractiveness, happiness, neuroticism, and self-esteem. J Psychol 1975; 90 (1st half): 27–30
Scher RK. Onychomycosis: a significant medical disorder. J Am Acad Dermatol 1996; 35 (3 Pt 2): S2–5
Coons SJ, Rao S, Keininger DL, et al. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000; 17 (1): 13–35
Lohr KN, Aaronson NK, Alonso J, et al. Evaluating quality of life and health status instruments: development of scientific review criteria. Clin Ther 1996; 18 (5): 979–92
Testa MA. Quality-of-life assessment in diabetes research: interpreting the magnitude and meaning of treatment effects. Diabetes Spectrum 2000; 13 (1): 29–35
Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297–334
Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York (NY): McGraw-Hill, 1994
Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979; 86 (2): 420–8
Cook TD, Campbell DT. Quasi-experimentation: design and analysis issues for field settings. Boston (MA): Houghton Mifflin, 1979
Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use. New York (NY): Oxford Medical Publications, 1996
Stewart AL, Ware JE, editors. Measuring functioning and well-being: theMedical Outcomes Study approach. Durham (NC): Duke University Press, 1992
Fleming JS, Courtney BE. The dimensionality of self-esteem. II: hierarchical facet models for revised measurement scales. J Pers Soc Psychol 1984; 46: 404–21
Ware JE, Snow KK, Kosinski M, et al. SF-36 Health Survey manual and interpretation guide. Boston (MA): The Health Institute, 1993
Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34 (3): 220–33
Dupuy HJ. The psychological general well-being (PGWB) index. In: Wenger NK, Mattson ME, Furberg CD, et al., editors. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: Le Jacq Publishing, 1984: 170–83
Nieworth M, Korting HC. Management of onychomycosis. Drugs 1999; 58 (2): 283–96
Roberts DT. Onychomycosis: current treatment and future challenges. Br J Dermatol 1999; 141 Suppl. 56: 1–4
Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27 Suppl. 3: S217–32
Deyo RA, Patrick DL. Barriers to the use of health status measures in clinical investigation, patient care, and policy research. Med Care 1989; 27 Suppl. 3: S254–68
Murawski MM, Miederhoff PA. On the generalizability of statistical expressions of health related quality of life instrument responsiveness: a data synthesis. Qual Life Res 1998; 7 (1): 11–22
Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993; 118 (8): 622–9
Epstein RS. Responsiveness in quality-of-life assessment: nomenclature, determinants, and clinical applications. Med Care 2000; 38 Suppl. II: II91–4
Bombardier C, Ware J, Russell IJ, et al. Auranofin therapy and quality of life in patients with rheumatoid arthritis: results of a multicenter trial. Am J Med 1986; 81 (4): 565–75
Temkin NR, Dikmen S, Machamer J, et al. General versus disease-specific measures: further work on the Sickness Impact Profile for head injury. Med Care 1989; 27 Suppl. 3: S44–53
Kennedy P. A guide to econometrics. 4th ed. Cambridge (MA): MIT Press, 1998
Burke LB. US regulation of pharmaceutical outcomes research. Value Health 2001; 4 (1): 5–7
Acknowledgements
The authors did not receive any payment for the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shaw, J.W., Joish, V.N. & Coons, S.J. Onychomycosis. Pharmacoeconomics 20, 23–36 (2002). https://doi.org/10.2165/00019053-200220010-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200220010-00003